5-amino-1mq human trial | 100mg Peptide Pen – Bioniq Lab 5-Amino-1MQ 50mg | Illuminated Peptides

Although gastric banding carries a lower risk of B12 deficiency than malabsorptive procedures such as Roux-en-Y bypass, reduced tolerance of B12-rich foods and the use of acid-suppressing medicines can still compromise nutritional status over time

Studies show that NNMT inhibition by 5-amino-1-methylquinolinium significantly reduces nicotinamide metabolism, increases NAM accumulation, improves NAD+ synthesis efficiency by over 30%, and markedly increases mitochondrial ATP production and cellular energy metabolism

In the 12-week randomised controlled trial documented in the obesity pharmacotherapy literature, the 1 mg/day group achieved statistically meaningful separation from placebo

Primary Research Areas NNMT enzymology and pharmacology the lead first-in-class selective small-molecule NNMT inhibitor used to validate the entire target class [1,2]